Patents by Inventor Wayne Luke

Wayne Luke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20250171421
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: June 24, 2024
    Publication date: May 29, 2025
    Inventors: Christopher NATALE, Patrick MOONEY, Tina GARYANTES, Wayne LUKE
  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20230382896
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: August 3, 2023
    Publication date: November 30, 2023
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick MOONEY, Tina GARYANTES, Wayne LUKE
  • Enantiomerically purified GPER agonist for use in treating disease states and conditions
    Patent number: 11760749
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Grant
    Filed: February 25, 2021
    Date of Patent: September 19, 2023
    Assignee: Linnaeus Therapeutics, Inc.
    Inventors: Christopher Natale, Patrick T. Mooney, Tina Garyantes, Wayne Luke
  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20220089576
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: May 24, 2021
    Publication date: March 24, 2022
    Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20220033385
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: February 25, 2021
    Publication date: February 3, 2022
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
  • Enantiomerically purified GPER agonist for use in treating disease states and conditions
    Patent number: 10934277
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: March 2, 2021
    Assignee: LINNAEUS THERAPEUTICS, INC.
    Inventors: Christopher Natale, Patrick T. Mooney, Tina Garyantes, Wayne Luke
  • ENANTIOMERICALLY PURIFIED GPER AGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20200140417
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: November 13, 2019
    Publication date: May 7, 2020
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
  • ENANTIOMERICALLY PURIFIED GPER ANGONIST FOR USE IN TREATING DISEASE STATES AND CONDITIONS
    Publication number: 20200024262
    Abstract: The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof, and 3) methods of treating or preventing disease states and conditions and cosmetic conditions mediated through these receptors and related methods thereof in humans and animals.
    Type: Application
    Filed: July 22, 2019
    Publication date: January 23, 2020
    Applicant: Linnaeus Therapeutics, Inc.
    Inventors: Christopher NATALE, Patrick T. MOONEY, Tina GARYANTES, Wayne LUKE
  • Benzothiophenes, formulations containing same, and methods
    Publication number: 20050239840
    Abstract: This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Type: Application
    Filed: March 30, 2005
    Publication date: October 27, 2005
    Inventors: Gordon Arbuthnot, Brian Dalder, Kerry Hartauer, Wayne Luke, Robert Stratford
  • Process for preparing benzoic acids
    Publication number: 20050137396
    Abstract: An improved process for the preparation of 4[(2-piperidin-1-yl)ethoxy]benzoic acid derivatives, comprising reacting a haloalkyl amine of formula (III) with a compound of formula (IV) in the presence of a hydrated inorganic base in an appropriate solvent.
    Type: Application
    Filed: December 22, 2003
    Publication date: June 23, 2005
    Inventor: Wayne Luke